News Lilly strikes again, buying Calytrix in $1.5bn deal Eli Lilly has added yet another name to its list of M&A deals this year after agreeing to buy blood disorder specialist Calytrix Bio for up to $1.5bn.
News MSD starts second phase 3 of Imago drug for blood cancers MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (M
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.